SYNRIBO (omacetaxine mepesuccinate) for injection Teva Pharmaceuticals announced that the FDA has approved Synribo (omacetaxine mepesuccinate) for Injection to treat adult patients with chronic phase ...
Teva's Synribo, a chronic myeloid leukemia (CML) treatment has been given final US approval after the company fulfilled a post-marketing commitment. The drug was approved by the FDA in October 2012, ...
Teva Pharmaceutical announced that the U.S. FDA approved SYNRIBO for Injection to treat adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance and/or ...
JERUSALEM — Teva Pharmaceutical Industries on Monday announced that the Food and Drug Administration approved Synribo (omacetaxine mepesuccinate) for injection, to include home administration. With ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t7bngk/synribo_chronic) has announced the addition of the "Synribo (Chronic ...
Teva has received US approval to market its Synribo injection for the treatment of the blood and bone cancer chronic myeloid leukaemia. The Food and Drug Administration (FDA) said the drug should be ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. This ...
JERUSALEM--(BUSINESS WIRE)--May 5, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine ...
JERUSALEM — Teva Pharmaceutical Industries on Thursday announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection. The drug is ...
The FDA approves Teva Pharmaceutical Industries' (NYSE:TEVA) Synribo (omacetaxine mepesuccinate) injection, for subcutaneous use, to include home administration. Now chronic myeloid leukemia patients ...
The US Food and Drug Administration has given the green light to Teva Pharmaceutical Industries' Synribo to treat chronic myelogenous leukaemia. The US Food and Drug Administration has given the green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback